Australia markets close in 56 minutes

GSK Jan 2025 37.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.65000.0000 (0.00%)
As of 12:22PM EDT. Market open.
Full screen
Previous close2.6500
Expiry date2025-01-17
Day's range2.6500 - 2.6500
Contract rangeN/A
Open interestN/A
  • Zacks

    Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug

    Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.


    FDA approves GSK's unique myelofibrosis treatment Ojjaara

    The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and anemia. This announcement comes after a three-month delay due to the need for additional data review.


    FDA approves GSK's Ojjaara for treatment of myelofibrosis-related anaemia

    The FDA has approved Ojjaara, a drug developed by GSK plc (LSE:GSK), for the treatment of intermediate or high-risk myelofibrosis in adults with anaemia, the pharmaceutical company announced on Monday. The approval comes following a three-month delay due to an FDA request for additional information.